FDA pathways to enhance evidence generation and information transparency for geriatric medicationWEI Hai-bo, XU Yang, DING Jing, YANG Yue1345-1351
Thoughts on the characteristics of priority review and approval of rare disease drugs in ChinaCHEN Qian-nan, LIU Xiao-xi, LIAN Gui-yu, HUANG Zhe1352-1357
Preparation and management of conditional approval drug package inserts in ChinaZHAO Ji-yu, TIAN Li-juan1358-1362
Globally approved deuterated drugs and patent research thereofMAO Hong-fen, LIN Tao-xi, HUANG Lu1363-1371
Progress in the implementation of conditional approval process for drugs in China:a pooled analysis from 2020 to 2024WANG Li, ZHAO Xiang-qi, LIAN Gui-yu, HUANG Zhe1372-1377
Prediction and analysis of Q-Marker for Shenge Bushen Capsules based on chemical composition and network pharmacologyYOU Pei-jin, HU Shi-xian, PU Chang-bing, HAO Juan, LÜ Zhi-yuan1378-1388
Effect of distal forearm peripheral nerve block with liposomal bupivacaine on rebound pain after peripheral nerve block and postoperative rehabilitation in patients with hand traumaZHANG Jing-hao, HE Rui-qi, XIAO Su-jun, ZHANG Xue-kang1389-1395
Retrospective analysis of sintilimab plus chemotherapy on peripheral blood immune cells in colorectal cancer patientsWANG Jian, WANG Xing-he, LIU Bin-yan1396-1402
Comparative efficacy of Chaihu Shugan San formula granules and traditional decoction pieces in treating chronic hepatitis B:a randomized controlled trialMEI Xue, TANG Xing, XU Xing-pei, DUAN Ding-shan, YU Cong-cong1403-1408
Characteristics analysis of clinical trial registration for CDK4/6 inhibitors based on the ClinicalTrials.gov and ChiCTR databasesZHANG Juan, LIU Xue-yan, YIN Gui-sen, YANG Si-tong1409-1416